Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial assessing CAN10 in systemic sclerosis and myocarditis

Next Previous
Trial Profile

A phase I trial assessing CAN10 in systemic sclerosis and myocarditis

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CAN 10 (Primary)
  • Indications Myocarditis; Systemic scleroderma
  • Focus Adverse reactions; First in man

Most Recent Events

  • 10 Nov 2023 According to a Cantargia media release,a dosing of healthy volunteers has started.
  • 13 Jan 2023 According to a Cantargia media release, following toxicology studies, once additional administrative procedures have been finalized, the company plans to submit an application to regulatory authorities to start the trial. The study start is dependent on timelines for regulatory review, but treatment of healthy volunteers could be initiated shortly following approval of the application.
  • 13 Jan 2023 According to a Cantargia media release, the company expects to start the trial during the first half of 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top